- Report
- October 2024
- 181 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- July 2024
- 150 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- March 2025
- 93 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- July 2024
- 135 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- July 2023
- 140 Pages
Global
From €4705EUR$4,949USD£3,952GBP
- Report
- October 2023
- 177 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- April 2023
- 120 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- May 2023
- 99 Pages
Global
From €3500EUR$3,944USD£3,043GBP
The Oncology Based In Vivo CRO market is a subset of the biotechnology industry that focuses on providing preclinical services for oncology drug development. These services include animal models, pharmacology, toxicology, and imaging studies. The goal of these services is to provide data that can be used to support the safety and efficacy of oncology drugs. The market is driven by the increasing demand for new treatments for cancer, as well as the need for more efficient and cost-effective drug development.
The Oncology Based In Vivo CRO market is highly competitive, with a number of companies offering services in this area. Some of the major players in the market include Charles River Laboratories, Covance, WIL Research, and Envigo. Other companies in the market include MPI Research, SRI International, and Taconic Biosciences. Show Less Read more
